Preclinical characterization of AZD1163, a first-in-class anti-PAD2/4 bispecific antibody for the treatment of rheumatoid arthritis
Gary P. Sims, Lacie Scaletta, John Andrews, Dorothy A. Sims, Martin Strain, Anna Sigurdardottir, Teneema Kuriakose, Elizabeth England, Lichchavi Rajasinghe, Fanyi Jiang, Ximing Xiong, Frances Neal, Lisa Vinall, Philip Newton, Elin Boger, Chong Kim, Helena Dahlbäck, Susanne Prothon, Jacob Leander, Er · 2026
Read Preclinical characterization of AZD1163, a first-in-class anti-PAD2/4 bispecific antibody for the treatment of rheumatoid arthritis by Gary P. Sims, Lacie Scaletta, John Andrews, Dorothy A. Sims, Martin Strain, Anna Sigurdardottir, Teneema Kuriakose, Elizabeth England, Lichchavi Rajasinghe, Fanyi Jiang, Ximing Xiong, Frances Neal, Lisa Vinall, Philip Newton, Elin Boger, Chong Kim, Helena Dahlbäck, Susanne Prothon, Jacob Leander, Er (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13085943.txt.
Description
Anti-citrullinated protein autoantibodies promote inflammation and joint tissue injury and define a poor prognostic group of patients with rheumatoid arthritis (RA). Citrullinated autoantigens that drive this autoimmune response are generated by peptidylarginine deiminase (PAD) enzymes, which are predominately expressed and released by neutrophils and monocytes.
Catalog record
| CREATOR | Gary P. Sims, Lacie Scaletta, John Andrews, Dorothy A. Sims, Martin Strain, Anna Sigurdardottir, Teneema Kuriakose, Elizabeth England, Lichchavi Rajasinghe, Fanyi Jiang, Ximing Xiong, Frances Neal, Lisa Vinall, Philip Newton, Elin Boger, Chong Kim, Helena Dahlbäck, Susanne Prothon, Jacob Leander, Er |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 79 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |